Sign Up to like & get
recommendations!
0
Published in 2022 at "Cancer Investigation"
DOI: 10.1080/07357907.2022.2093895
Abstract: Abstract Despite the incorporation of trastuzumab biosimilars (to treat HER2-positive breast cancer) in clinical practice guidelines, gaps remain such as patient and clinician education. We hosted a webinar comprised of a panel of biosimilars experts,…
read more here.
Keywords:
biosimilars planning;
trastuzumab biosimilars;
trastuzumab;
resource trastuzumab ... See more keywords